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Nonalcoholic fatty liver disease (NAFLD) is closely related with obesity. However, obese
subjects, generally represented by high BMI, do not always develop NAFLD. A number of
possible causes of NAFLD have been studied, but the exact mechanism has not yet been
elucidated.
Methods
A total of 304 consecutive subjects who underwent general health examinations including
abdominal ultrasonography, transient elastography and abdominal fat computed tomogra-
phy were prospectively enrolled. Significant steatosis was diagnosed by ultrasonography
and controlled attenuation parameter (CAP) assessed by transient elastography.
Results
Visceral fat area (VFA) was significantly related to hepatic steatosis assessed by CAP,
whereas body mass index (BMI) was related to CAP only in univariate analysis. In multiple
logistic regression analysis, VFA (odds ratio [OR], 1.010; 95% confidence interval [CI],
1.001–1.019; P = 0.028) and triglycerides (TG) (OR, 1.006; 95% CI, 1.001–1.011; P =
0.022) were independent risk factors for significant hepatic steatosis. The risk of significant
hepatic steatosis was higher in patients with higher VFA: the OR was 4.838 (P<0.001; 95%
CI, 2.912–8.039) for 100<VFA200 cm2 and 7.474 (P<0.001; 95% CI, 2.462–22.693) for
VFA >200 cm2, compared to patients with a VFA100 cm2.
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Conclusions
Our data demonstrated that VFA and TG is significantly related to hepatic steatosis
assessed by CAP not BMI. This finding suggests that surveillance for subjects with NAFLD
should incorporate an indicator of visceral obesity, and not simply rely on BMI.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver
disease worldwide. Severe forms of NAFLD such as nonalcoholic steatohepatitis can progress
to end-stage liver disease such as cirrhosis or hepatocellular carcinoma [1–3]. Therefore, inves-
tigating risk factors associated with hepatic steatosis is required to perform effective screening.
Hepatic steatosis develops for a variety reasons, but obesity is the most common associated
condition [4] and vice versa. Cuf-off of body mass index (BMI) defining obesity differs accord-
ing to race. The recommended BMI cut-off value for obesity is > 25 kg/m2 for Asians, in con-
trast to> 30 kg/m2 for Western individuals [5]. However, NAFLD can occur in non-obese
subjects and NAFLD in non-obese patient is especially frequent in Asia [6].
Liver biopsy is the gold standard for diagnosing fatty liver disease, but it is invasive and dif-
ficult to perform in a clinical setting. As a non-invasive method, transient elastography (TE)
has been validated for assessing hepatic steatosis using a controlled attenuation parameter
(CAP) [7]. In a recent study, the CAP score and liver stiffness values assessed by TE showed
significant correlation with the degrees of steatosis (r = 0.656, P<0.001) and fibrosis (r = 0.714,
P<0.001) [8]. A meta-analysis also showed that CAP provides a standardized non-invasive
measurement of hepatic steatosis [9].
Several studies suggested visceral adiposity to be a clinical predictor of hepatic steatosis
[10–12]. Visceral fat area (VFA) measured by computed tomography (CT) is a quantitative
and accurate measure of visceral fat, which is more predictive of hepatic steatosis than BMI or
subcutaneous fat accumulation [13,14]. Although previous studies have identified a relation-
ship between VFA and histological hepatic steatosis, the relationship between VFA and steato-
sis is not widely used in clinical practice due to the invasiveness of liver biopsy [15]. To
facilitate clinical application, the relationship between VFA and non-invasive methods of
assessing hepatic steatosis should be evaluated.
As a non-invasive and relatively accurate method of quantifying hepatic steatosis, CAP has
other advantages, such as operator independency, and lower costs, when compared to other
non-invasive methods such as ultrasonography, CT, and magnetic resonance imaging (MRI)
[16–20]. However, the relationship between CAP and clinical factors, such as indicators of vis-
ceral adiposity, is still unclear. The aim of this study was to evaluate the relationship between
CAP and VFA (quantitative indicators of hepatic steatosis and central obesity, respectively),
together with other clinical factors.
Materials
Patients
Between November 2011 and July 2012, 316 patients who underwent a general health exami-
nation that included abdominal ultrasonography, TE, and abdominal fat CT scan at Severance
Hospital, Yonsei University College of Medicine, Seoul, Korea, were enrolled. Patients were
excluded if they chronically consumed excessive alcohol (>30 g/day for men, >20 g/day for
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BMI, body mass index; CAP, controlled attenuation
parameter; CI, confidence interval; CT, computed
tomography; ESR, erythrocyte sedimentation rate;
IQR, interquartile range; MRI, magnetic resonance
imaging; NAFLD, nonalcoholic fatty liver disease;
NPV, negative predictive value; OR, odds ratio;
PPV, positive predictive value; SD, standard
deviation; SFA, subcutaneous fat area; TAT, total
adipose tissue area; TE, transient elastography;
VFA, visceral fat area; WHR, waist-hip-ratio; γ-GTP,
γ-glutamyl transpeptidase.
women) or were positive for serum hepatitis B surface antigen, or serum hepatitis C virus anti-
body. We also excluded patients in whom CAP measurements were unsuccessful. Finally, 304
patients were included in the statistical analysis. Written informed consent was obtained from
all patients before enrollment. The study protocol conformed to the ethical guidelines of the
1975 Helsinki Declaration and was approved by the Institutional Review Board of Severance
Hospital.
Anthropometric data and laboratory tests
Clinical data and previous medical history were obtained by self-report questionnaires and an
electronic chart review. Anthropometric measurements, including BMI, and waist-hip ratio
(WHR), were performed on the same day as the laboratory and radiological tests. Body weight
and height were measured using a digital scale, and BMI was calculated by dividing weight
(kg) by the square of height (m2). Using a tape measure, a well-trained individual measured
the waist circumference at the midpoint between the lower costal margin and anterior superior
iliac crest, and the hip circumference at the widest point over the buttocks. WHR was obtained
by dividing the mean waist circumference by the mean hip-circumference.
Laboratory parameters including serum fasting glucose, total cholesterol, triglycerides,
aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transpeptidase
(γ-GTP) and erythrocyte sedimentation rate (ESR) were measured on the same day as the
radiological tests.
Ultrasonographic assessments and measurement of controlled
attenuation parameter
After fasting for at least 8 hours, all patients underwent abdominal ultrasonography and TE
using the liver FibroScan1 (Echosens, Paris, France) M probe. Ultrasonographic examinations
of the liver were performed by experienced radiologists who were blinded to the clinical infor-
mation. Diagnosis of a fatty liver was performed by ultrasonography using previously
described standardized criteria [21].
One experienced technician performed TE blinded to the clinical data of the patients’. The
principles of CAP measurement have been described previously [16]. CAP measures ultrasonic
attenuation at 3.5 MHz using signals acquired by TE. The interquartile range (IQR) was
defined as an index of the intrinsic variability of CAP values corresponding to the interval of
CAP results containing 50% of the valid measurements between the 25th and 75th percentiles.
The median of successful measurements was selected as representative of the CAP values of a
given patient. As an indicator of variability, the ratio of the IQR of CAP values to the median
(IQR/MCAP) was calculated. In this study, only TE measurements with 10 valid shots, and a
success rate of 60% were considered reliable and used for statistical analysis.
Steatosis ( TE based steatosis grade 1), was defined as the presence of fatty liver disease by
abdominal ultrasonography findings and a CAP value 248 dB/m. Significant steatosis ( TE
based steatosis grade 2) was defined as the presence of fatty liver disease on the images and a
CAP value 268 dB/m [9].
Assessment of abdominal visceral fat area and subcutaneous fat area
Subcutaneous and visceral fat areas were calculated by CT (Somatom Plus, Siemens, Ger-
many). A lead protection device was used to minimize exposure to X-rays during CT scans.
Subjects were examined in a supine position. The visceral and subcutaneous adipose regions
were calculated according to the intervertebral position of L2–3. VFA was defined as intra-
abdominal fat bound by the parietal peritoneum or transversals fascia, excluding the vertebral
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column and the paraspinal muscles. Subcutaneous fat area (SFA) was defined as fat superficial
to the abdominal and back muscles. VAT was then measured around the inner boundary of
the abdominal wall muscles. A region of interest drawn around the external margin of the der-
mis was used to calculate the total adipose tissue (TAT) area. The SFA was obtained by sub-
tracting the VAT from the TAT.
Statistical analysis
Data are expressed as mean ± standard deviation, median (range), or number (%), as appropri-
ate. Correlations between CAP and other variables were described using Spearman’s correla-
tion coefficients. Comparisons between patients with and without hepatic steatosis were
performed using the Student’s t-test or the Mann-Whitney test for continuous variables, and
the chi-squared or Fisher’s exact test was used for categorical variables. Univariate and subse-
quent multivariate binary logistic regression analyses were performed to identify independent
factors related to significant hepatic steatosis. Odds ratio (OR) and corresponding 95% confi-
dence interval (CI) were also evaluated. Optimal cut-off VFA values to predict significant
hepatic steatosis were calculated as the maximized sum of the sensitivity and specificity (You-
den index) from the areas under the receiver operating characteristic curves (AUROC). Posi-
tive predictive value and negative predictive value (PPV and NPV) were also computed. A P
value <0.05 by two-tailed test was considered indicative of statistical significance. Data analy-
ses were performed using the SAS software (ver. 9.1; SAS Inc., Cary, NC, USA).
Results
Baseline characteristics
Baseline characteristics of the study population are summarized in Table 1. The total number
of subjects was 304 (165 men and 139 females) and their mean age was 56.5 ± 10.7 years. The
mean BMI was 24.1 ± 3.1 kg/m2, and the WHR was 0.89 ± 0.04. Eighty (26.3%) patients were
overweight (BMI, 23–25 kg/m2) and 114 (37.5%) were obese (BMI >25 kg/m2) according to
the new World Health Organization BMI criteria for Asians.[22] The mean VFA and SFA
were 111.4 ± 50.6 cm2 and 175.3 ± 60.0 cm2, respectively. The median CAP value was 244 dB/
m (range, 100–382).
BMI, WHR, VFA, CAP value, and the serum levels of fasting glucose, triglycerides, AST,
ALT, γ-GTP, and ESR were higher in males, whereas SFA and the serum cholesterol level were
higher in females (Table 1).
Correlations between controlled attenuation parameter and clinical
variables
In univariate analyses, CAP values were correlated with the male gender (ρ = 0.173, P = 0.002),
BMI (ρ = 0.491, P<0.001), VFA (ρ = 0.497, P<0.001), SFA (ρ = 0.234, P<0.001), fasting glu-
cose (ρ = 0.406, P<0.001), triglycerides (ρ = 0.352, P<0.001), ALT (ρ = 0.285, P<0.001), and γ
-GTP (ρ = 0.374, P<0.001). In a subsequent multivariate regression analysis, CAP (P = 0.001)
was independently associated with VFA, triglycerides (P<0.001) and ALT (P = 0.017)
(Table 2). The correlation between CAP and VFA is shown in S1 Fig.
Comparison of the hepatic steatosis and non-hepatic steatosis groups
Significant hepatic steatosis was observed in 134 (44.1%) patients. Significant steatosis was
present in 93 (69.4%) patients (68 in male and 25 in female) in the obese group and 41 (30.6%)
patients (21 in male and 20 in female) in the non-obese group.
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In univariate analysis, male gender (90 of 134 patients [67.2%] vs. 49 of 170 patients
[28.8%], P = 0.005), BMI (25.5 ± 3.1 kg/m2 vs. 23.0 ± 2.6 kg/m2, P<0.001), WHR (0.90 ± 0.04
vs. 0.86 ± 0.04, P = 0.001), VFA (131.5 ± 53.7 cm2 vs. 95.6 ± 41.9 cm2, P<0.001), SFA
(191.3 ± 60.8 vs. 162.7 ± 56.5, P<0.001), fasting glucose (104.8 ± 23.8 mg/mL vs. 95.7 ± 23.7
mg/mL, P = 0.001), triglycerides (133.8 ± 71.4 mg/mL vs. 100.1 ± 52.6 mg/mL, P<0.001), ALT
(26.5 ± 16.1 IU/L vs. 20.5 ± 10.4 IU/L, P<0.001), and γ-GTP (37.5 ± 32.3 IU/L vs. 29.8 ± 29.5
IU/L, P = 0.031) were higher in patients with significant hepatic steatosis than in those without
(Table 3). When the patients with and without significant hepatic steatosis were compared
Table 1. Baseline characteristics (n = 304).
Variables Total (n = 304) Male group (n = 165, 54.3%) Female group (n = 139, 45.7%) P-value
Age, years 56.5 ± 10.7 56.6 ± 10.9 56.3 ± 10.6 NS
Medical history
Diabetes mellitus 22 (7.2) 16 (9.7) 6 (4.3) NS
Hypertension 44 (14.5) 29 (17.6) 15 (10.8) NS
Body mass index, kg/m2 24.1± 3.1 25.1 ± 3.0 22.9 ± 2.7 <0.001
Waist/Hip ratio 0.89 ± 0.04 0.89 ± 0.04 0.86 ± 0.04 <0.001
Visceral fat area, cm2 111.4±50.6 123.5 ± 53.7 97.1 ± 42.6 <0.001
Subcutaneous fat area, cm2 175.3 ± 60.0 167.3 ± 60.3 184.8 ± 58.5 0.011
Laboratory profiles
Fasting glucose. mg/mL 99.7 ± 24.2 104.6 ± 27.8 93.9 ± 17.4 <0.001
Total cholesterol, mg/mL 184.5 ± 37.8 178.0 ± 39.1 192.1 ± 34.7 0.001
Triglycerides. mg/mL 114.9 ± 63.7 128.6 ± 74.3 98.8 ± 43.2 <0.001
AST, IU/L 22.9 ± 9.0 24.3 ± 8.8 21.4 ± 7.9 0.003
ALT, IU/L 23.5 ± 13.5 26.6 ± 14.7 19.1 ± 10.5 <0.001
γ-GTP, IU/L 33.2 ± 30.9 42.7 ± 36.4 22.1 ± 17.3 0.001
ESR, mm/h 17.2 ± 15.5 13.4 ± 13.3 21.9 ± 16.8 <0.001
CAP (dB/m) 244 (100–382) 254 (127–367) 235 (100–382) 0.001
IQR (dB/m) 28.0 (7.0–75.0) 26.0 (7.0–65.0) 29 (8.0–75.0) NS
IQR/Mcap 0.12 (0.02–0.25) 0.11 (0.02–0.21) 0.12 (0.02–0.25) NS
Variables are expressed as mean ± standard deviation, median (range), or number (%). NS, not significant (P>0.05); AST, aspartate aminotransferase;
ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase; ESR, erythrocyte sedimentation rate; CAP, controlled attenuation parameter; IQR,
interquartile range
https://doi.org/10.1371/journal.pone.0187066.t001
Table 2. Univariate and multivariate regression analyses of clinical factors associated with controlled attenuation parameter.
Variable Univariate Multivariate
ρ P value (ρ) P value
Male gender 0.173 0.002 NS
Body mass index, kg/m2 0.491 <0.001 NS
Visceral fat area, cm2 0.497 <0.001 0.001
Subcutaneous fat area, cm2 0.234 <0.001 NS
Fasting glucose, mg/mL 0.406 <0.001 NS
Triglycerides, mg/mL 0.352 <0.001 <0.001
ALT, IU/L 0.285 <0.001 0.017
γ-GTP, IU/L 0.374 <0.001 NS
NS, not significant; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase
https://doi.org/10.1371/journal.pone.0187066.t002
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according to gender, BMI, WHR, VFA, SFA, and serum level of fasting glucose, triglycerides,
ALT, and γ-GTP were significantly higher in both genders with significant hepatic steatosis
(S1 Table).
Risk factors for significant hepatic steatosis
In the multiple logistic regression analysis adjusted for age and gender, VFA (OR, 1.010; 95%
CI, 1.001–1.019; P = 0.028) and triglycerides (OR, 1.006; 95% CI, 1.001–1.011; P = 0.022) were
identified as independent risk factors for significant hepatic steatosis (Table 4). VFA exhibited
Table 3. Comparison of patients with and without significant hepatic steatosis.
Variable No significant-hepatic steatosis (n = 170, 55.9%) Hepatic steatosis (n = 134, 44.1%) P value
Age, years 55.5 ± 11.5 57.7 ± 9.7 NS
Male gender (%) 49 (36.6) 90 (52.9%) 0.005
Medical history
Diabetes mellitus 7 (4.1) 15 (11.2) NS
Hypertension 26 (15.3) 18 (13.4) NS
Body mass index, kg/m2 23.0 ± 2.6 25.5 ± 3.1 <0.001
Waist/hip ratio 0.86 ± 0.04 0.90 ± 0.04 0.001
Visceral fat area, cm2 95.6 ± 41.9 131.5 ± 53.7 <0.001
Subcutaneous fat area, cm2 162.7 ± 56.5 191.3 ± 60.8 <0.001
Laboratory profiles
Fasting glucose, mg/mL 95.7 ± 23.7 104.8 ± 23.8 0.001
Cholesterol, mg/mL 182.3 ± 39.6 187.4 ± 35.3 NS
Triglycerides, mg/mL 100.1 ± 52.6 133.8 ± 71.4 <0.001
AST, IU/L 21.9 ± 7.2 24.3 ± 9.8 NS
ALT, IU/L 20.5 ± 10.4 26.5 ± 16.1 <0.001
γ-GTP, IU/L 29.8 ± 29.5 37.5 ± 32.3 0.031
ESR, mm/h 17.1 ± 15.1 17.6 ± 16.2 NS
Liver stiffness value, kPa 4.5 (2.1–21.8) 4.6 (2.8–14.3) NS
Variables are expressed as mean ± standard deviation, median (range), or number (%).
NS, not significant; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase; ESR, erythrocyte sedimentation
rate
https://doi.org/10.1371/journal.pone.0187066.t003
Table 4. Independent risk factors for significant hepatic steatosis.
Variable Total (n = 304) Male (n = 165, 54.3%) Female (n = 139, 45.7%)
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Male gender NS
Age NS NS NS
BMI NS NS NS
Visceral fat area 1.010 (1.001–1.019) 0.028 1.008 (1.001–1.011) 0.045 1.029 (1.010–1.048) 0.002
Subcutaneous fat area NS NS NS
Fasting glucose NS NS NS
Triglycerides 1.006 (1.001–1.011) 0.022 NS 1.003 (1.006–1.026) 0.017
ALT NS NS 1.057 (1.006–1.111) 0.029
γ-GTP NS NS NS
OR, odds ratio; CI, confidence interval; NS, not significant; BMI, body mass index; ALT, alanine
https://doi.org/10.1371/journal.pone.0187066.t004
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a greater AUROC values than SFA and WHR (VFA, 0.750; SFA, 0.597; WHR, 0.721) (Fig 1).
VFA (OR, 1.008; 95% CI, 1.001–1.011; P = 0.045) was the only independent risk factor for sig-
nificant hepatic steatosis in males, whereas VFA (OR, 1.029; 95% CI, 1.010–1.048; P = 0.002),
triglycerides (OR, 1.003; 95% CI, 1.006–1.026; P = 0.017), and ALT (OR, 1.057; 95% CI, 1.006–
1.111; P = 0.029) were independent risk factors in females.
Optimal cut-off visceral fat area values for predicting significant hepatic steatosis. The
cut-off VFA value for predicting a low risk of significant hepatic steatosis with a high NPV
(92.3%) was 57.3 cm2 (PPV, 47.5%; sensitivity 98.5%; specificity 14.1%). The cut-off value of
VFA for predicting a high risk of significant hepatic steatosis with a high PPV (70.0%) was
192.2 cm2 (NPV 57.7%; sensitivity 10.4%; specificity 96.5%).
When the population was stratified according to VFA <100 cm2, 100VFA<200 cm2, and
VFA200 cm2, patients with a higher VFA had a greater risk of significant hepatic steatosis.
The ORs were 4.838 (P<0.001; 95% CI, 2.912–8.039) for patients with 100VFA<200 cm2
and 7.474 (P<0.001; 95% CI, 2.462–22.693) for those with a VFA200 cm2, as compared to
patients with a VFA <100 cm2. The median CAP score and LS value increased with increasing
VFA (Fig 2A and 2B).
Sub-group analysis of patients with a body mass index below 23 kg/m2
To identify risk factors for significant hepatic steatosis in non-obese patients, sub-group analy-
sis of subjects with a BMI<23 kg/m2 was performed. Among 110 patients (76 males and 34
Fig 1. Areas under the receiver operating characteristic curves of the predictive power of hepatic
steatosis.
https://doi.org/10.1371/journal.pone.0187066.g001
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females), 22 (20.0%) had significant hepatic steatosis. In univariate analyses, VFA (P<0.001),
glucose (P = 0.009), and triglycerides (P = 0.001) were associated with significant hepatic stea-
tosis. In a subsequent multivariate analysis, only VFA was significantly related to significant
hepatic steatosis (OR 1.006; 95% CI 1.001–1.011; P = 0.022).
Discussion
NAFLD has become one of the most important and rapidly increasing diseases worldwide.[1]
Metabolic syndrome, including obesity, has surprisingly become a major health problem in
Asia in association with a changed in lifestyle. Our data suggest that VFA is significantly asso-
ciated with hepatic steatosis, as assessed by TE. Patients with a higher VFA had a greater risk
of significant hepatic steatosis compared with those with a lower VFA. When the population
was stratified according to VFA, patients with a higher VFA had a greater risk of significant
hepatic steatosis, exhibited by a higher OR. The association between VFA and hepatic steatosis
was independent of BMI. Moreover, VFA was predictive of hepatic steatosis not only in obese
subjects but also in non-obese subjects.
Obesity is a well-known risk factor for metabolic diseases, including NAFLD. Previous
studies reported that BMI is strongly correlated with fatty liver and the risk of NAFLD
increases with increasing BMI [23,24]. However, there is growing evidence that visceral adipo-
city rather than total adipocity reflects ectopic fat accumulation. Thus, visceral adiposity is the
harmful aspect of the metabolic syndrome. Although BMI and waist circumference are used as
surrogate markers of obesity, they have limited ability to discriminate between visceral and
subcutaneous fat compartments [25,26]. Therefore, the aim of our study was to assess the asso-
ciation between visceral fat and hepatic steatosis independently of total adiposity. Our results
suggest that VFA is significantly associated with hepatic steatosis, whereas other obesity indi-
cators, such as BMI, are not. This finding is in line with those of previous studies [10,27]. In
our study, VFA was predictive of NAFLD irrespective of gender or obesity.
Previous studies showed a relatively low prevalence of NAFLD (6.3%-34.0%) when ultraso-
nography was used for diagnosis [28]. Because ultrasonography is a subjective examination
Fig 2. (A) Controlled attenuation parameter (CAP) score distribution in patients with visceral fat area (VFA) <100 cm2, 100VFA<200 cm2, and VFA
200 cm2. The median CAP score increased with increasing VFA. (B) Liver stiffness (LS) value distribution in patients with visceral fat area (VFA)
<100 cm2, 100VFA<200 cm2, and VFA200 cm2. The median LS value increased with increasing VFA.
https://doi.org/10.1371/journal.pone.0187066.g002
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that is highly dependent on the operator, and insensitive in mild (<30%) intrahepatic steatosis,
the prevalence of NAFLD may have been underestimated [29]. By comparison, the CAP value,
measured using TE, can detect hepatic steatosis involving as little as 10% of hepatocytes [30].
Although it is often impossible to evaluate the degree of steatosis with ultrasonography in
obese subjects, TE can evaluate the degree of steatosis accurately in these patients.
Asian tends to comprise a greater proportion of non-obese patients with NAFLD than
Western populations. The prevalence of NAFLD was 7.3% in a group of non-obese Chinese
patients, with an incidence of 8.9% during the 5-year follow-up [31]. In Korea, the prevalence
of NAFLD in non-obese subjects was 23.4%, similar to our findings [32]. Among 110 patients
with a BMI <23 kg/m2, 22 (20.0%) had significant hepatic steatosis. The distributions of body
fat and total amount of adipose tissue are important in the development of NALFD in non-
obese patients [33]. Central obesity, including truncal and visceral obesity, is more strongly
correlated with NAFLD development than an increase in BMI in non-obese patients [34,35].
Thus, VFA was expected to be a stronger predictor than BMI in both obese and non-obese
patients. However, age and BMI were associated with NAFLD in obese Korean subjects, but
not in non-obese subjects [32]. In our study, the cut-off VFA value for predicting a low risk of
significant hepatic steatosis was 57.3 cm2 and the value for predicting a high risk was 192.2
cm2. In a previous Korean study, the cut-off VFA value associated with an increased risk of
obesity-related disorders was 71.10 cm2 (sensitivity, 72.3%; specificity, 76.5%; P = 0.01) for
patients aged 16 to 18 years [36]. The cut-off values differed according to age, but VFA consis-
tently had a greater impact on obesity-related outcomes than did BMI.
This study had limitations. First, histological assessment was not available. Because the sub-
jects were undergoing health check-ups, most refused a liver biopsy due to its invasiveness.
The gold standard of diagnosis is still a liver biopsy, but recent studies for non-invasive mark-
ers including CAP are under way to replace liver biopsy [37]. Second, the cut-off CAP value
for hepatic steatosis is controversial. In this study, the cut-off value (248 dB/m) was deter-
mined according to previous reports on the accuracy of CAP based on a meta-analysis data.
However, our group has experience validating CAP scores according to histologic steatosis in
patients with NAFLD [8,9]. The optimal cut-off values for steatosis were 247 dB/m for S1, 280
dB/m for S2, and 300 dB/m for S3. Third, CT scan had concerns about the cost and risk of
radiation exposure. Thus, CAP is preferred due to radiation-free assessment. However, fat CT
is very safe and relatively low exposure to radiation with an examination time of 3 min and a
radiation exposure of only 2 mSV. It is usually half of the low-dose chest CT (5mSV) for early
diagnosis of lung cancer. Lastly, sarcopenia has recently been identified as an important factor
in NAFLD, but it has not been evaluated in this study.
In conclusion, VFA was significantly correlated with hepatic steatosis measured by CAP.
VFA was not affected by gender or other factors. Thus, patients with NAFLD require specific
surveillance, which should involve parameters indicative of central obesity and, not only BMI.
Supporting information
S1 Fig. Correlation between controlled attenuation parameter(CAP) value and visceral fat
area (VFA). The regression line is shown. CAP was significantly correlated with VFA
(P<0.001).
(TIF)
S1 Table. Comparison of patients with and without significant hepatic steatosis subdivided
by gender.
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